Letter to the Editor: mRNA Vaccines in Urological Malignancies

Xu H , Zheng X , Zhang S , et al. Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma. Mol Cancer, 2021; 20:159.

Zheng X , Xu H , Yi X , et al. Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine. Mol Cancer, 2021; 20:160.

Heiser A , Coleman D , Dannull J , et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest, 2002; 109:409–417.

Su Z , Dannull J , Heiser A , et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res, 2003; 63:2127–2133.

Mu LJ , Kyte JA , Kvalheim G , et al. Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer, 2005; 93:749–756.

Kübler H , Scheel B , Gnad-Vogt U , et al. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. J Immunother Cancer, 2015; 3:26.

Rausch S , Schwentner C , Stenzl A , et al. mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer. Hum Vaccin Immunother, 2014; 10:3146–3152.

Rittig SM , Haentschel M , Weimer KJ , et al. Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy. Oncoimmunology, 2016; 5:e1108511.

Lilleby W , Tryggestad AM , Bigalke I , et al. Biochemical relapse in very high-risk prostate cancer after radical prostatectomy and DC-vaccine loaded with tumor RNA, hTERT, and survivin. J Clin Oncol 2020;38:324-.

Amin A , Dudek AZ , Logan TF , et al. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results. J Immunother Cancer, 2015; 3:14.

Figlin RA , Tannir NM , Uzzo RG , et al. Results of the ADAPT phase 3 study of rocapuldencel-T in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma. Clin Cancer Res, 2020; 26:2327–2336.

Kongsted P , Borch TH , Ellebaek E , et al. Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: a randomized phase II study. Cytotherapy, 2017; 19:500–513.